Hers Pricing: What Determines Your Monthly Total

Published within the PlexusDx Education Hub, our resource for grounded guidance on GLP-1 therapies, weight-management protocols, and the genetic variables shaping each metabolic choice. Browse all Peptides & GLP-1 education

An independent editorial review. PlexusDx has no commercial relationship with Hers or its parent, and this page carries no affiliate links or compensation.

Hers is one of many telehealth programs in the GLP-1 and weight-management space. Here the focus is savings mechanics, how price reductions actually surface in a subscription model, who tends to qualify, and where a lower number changes nothing about the underlying biology. Fair-balance framing, not a buying recommendation. Current as of April 2026.

How savings surface in cash-pay GLP-1 programs

Hers, the women's brand of Hims & Hers Health, sells weight management as a subscription rather than an insurance-billed benefit. In that model, a discount is not a code redeemed against a pharmacy claim; it is whatever price adjustment the brand chooses to build into its own offer, such as an introductory rate or a longer-commitment tier. Whatever is currently available is posted on Hers's official website.

Who tends to qualify for a lower price

Because pricing is internal to the program, eligibility for any reduction follows the brand's own rules: the medication you are prescribed, the subscription tier you choose, and whether you are billed for an FDA-approved brand product from a retail pharmacy or a compounded preparation from a 503A compounding pharmacy. There is no external qualification step the way an insurance formulary would impose one.

What a lower price still cannot change

A discount adjusts the bill, not the medicine. Across the telehealth GLP-1 market as of April 2026, monthly totals typically fall between roughly $200 and $700+, with wide variance, and a promotional rate simply moves you within that band. The compounds themselves, GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual agonist tirzepatide, carry the same evidence at any price: STEP (NEJM, 2021), SURMOUNT (NEJM, 2022), and SURMOUNT-OSA (NEJM, 2024). Confirm live pricing at Hers's official website.

The upstream factor no discount touches

The saving that matters most has nothing to do with price. Telehealth programs like this one do not examine the upstream genetic architecture that shapes every GLP-1 response. Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene, the direct target of every GLP-1 compound), MC4R (a melanocortin receptor central to satiety and energy balance), and TCF7L2 (a transcription factor tied to glucose homeostasis and GLP-1 secretion) map the baseline metabolic terrain any compound acts on. These are pathway-level markers. They do not predict response to a specific medication, but they describe the biology a clinician is prescribing into, context a prescription alone never captures.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What distinguishes the approach is that upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO and MC4R, and TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Reading that profile alongside the protocol is the test before you invest approach, turning guesswork into an informed conversation with your healthcare provider.

Not affiliated: PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1, GLP 1 What Is.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols, and this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways; it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Rather than chase a discount, see the Weight Management Protocols, semaglutide and tirzepatide paired with the genetic context most telehealth programs omit. Or start upstream and take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions About Hers Discounts

How do Hers discounts actually work?

In a cash-pay subscription model, a discount is a price adjustment the brand builds into its own offer, such as an introductory rate, not an external code redeemed against insurance. Whatever is currently available appears on the brand's own site and changes over time.

Is there a first-order or bundle discount?

Some programs offer introductory or longer-commitment pricing, but terms vary and are set by the brand. Any such reduction still moves you within the broader market band of roughly $200 to $700+ per month as of April 2026, depending on compound and tier.

Do discounts depend on the medication chosen?

Often, yes. Because pricing follows the compound, the subscription tier, and whether dispensing is brand or compounded, a discount may apply to one product and not another. Read which medication and tier an offer covers before assuming it applies to your situation.

Should price alone drive a GLP-1 decision?

Price matters, but it says nothing about how your body will respond. Pathway-level variants in FTO and MC4R, and TCF7L2 shape baseline GLP-1 biology regardless of what you pay, which is why upstream genetic context belongs in the decision alongside cost.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education